Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Elevated levels of lipoprotein (a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.

Energy Transfer LP (ET) closed at $17.15 in the latest trading session, marking a +1.12% move from the prior day. This move ...

Please provide your email address to receive an email when new articles are posted on . Investigational therapies to lower Lp(a) include antisense oligonucleotide therapies and small interfering RNA ...

Please provide your email address to receive an email when new articles are posted on . Lipoprotein(a) should be measured in all people at least once. “Evaluation and management of Lp(a) is actionable ...

CHICAGO, IL—Two new drugs targeting lipoprotein(a)—one a small interfering RNA (siRNA), the other an oral agent that prevents its formation—both showed positive results in early phase II studies, with ...

The evidence implicating high levels of lipoprotein(a), or Lp(a), as a risk predictor for heart attack, stroke, and other cardiovascular conditions has outpaced the science of what to do about the ...

Among people with low levels of LDL cholesterol—even those who achieve very large absolute reductions with statin therapy—higher levels of lipoprotein(a) are associated with an increased risk of ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--LP Building Solutions (LP), a leading manufacturer of high-performance building products, announced contributions exceeding $1.3 million in 2024 through the LP ...